MOTUS GI, INC.
FT. LAUDERDALE, FLORIDA

Motus GI Holdings, Inc. is a medical technology company dedicated to improving endoscopy outcomes and experiences. We are currently focused on bringing to market the Pure-Vu® System which is designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The Pure-Vu® System has the potential to improve the colonoscopy experience for physicians, patients and payers by diminishing the dependency on pre-procedural preparations, thereby enhancing the quality and cost-effectiveness of the exam. Interested in joining our team? We're looking for experienced, dedicated, passionate problem-solvers and innovators like you. Prior to joining Motus GI in 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems. Other previous positions include serving as a Vice President at Cordis, a Johnson & Johnson company, and in senior leadership roles at Cardiac Pathways Corporations and Cardiovascular Imaging Systems, both acquired by Boston Scientific Corporation. Mr. Taylor has over 20 years of experience serving as a financial officer, operating executive and business advisor across start-ups, emerging growth and Fortune 500 companies in both the U.S. and abroad. Prior to joining Motus GI in August 2017, Mr. Taylor was President and Chief Financial Officer of Angel Medical Systems, Inc., a medical device company that develops and manufactures continuous intra-cardiac ischemia monitoring and alerting systems. While at Angel Medical Systems, Mr. Taylor supervised the operations of more than fifty (50) employees in the United States and Brazil, while also overseeing the financial planning and analysis activities, capital raising efforts, and implementation of capital and operating budgets. Prior to his time at Angel Medical Systems, Mr. Taylor served as a Practice Leader for AC Lordi Consulting, a professional services firm, providing finance, accounting and strategy services. Before joining AC Lordi, Mr. Taylor was the Chief Financial Officer and Corporate Director of Operations for Safe3w, Inc., a security software company, which was acquired by iPass (NASDAQ: IPAS) in 2004. Before coming to Motus GI in 2013, Hagit Ephrath spent 11 years with Given Imaging—the world leader in capsule endoscopy. Prior to that, she worked in the blood glucose monitoring business of Carmel Biosensor. James has over 30+ years of cross functional Medical Device experience with the last 13 years focused on leading Quality organizations, most recently for 4 years as a company Quality Director in the diabetes care industry, and prior to that as managing Corporate Design Assurance at Boston Scientific. His previous roles, at both start-up's & large organizations, have included R&D engineering, as well leading Manufacturing & Process Development Engineering departments. This has provided both the ability to not only meet organizational Quality goals, but also partner on the engineering solutions to ensure business success. Mr. Balog has extensive knowledge in product management, project management, product roadmap development, engineering, operations and production. Prior to joining Motus GI in June 2017, Mr. Balog served as the Director of Operations and Engineering at EndoChoice. Earlier, he served as Director of Product Management at Given Imaging, Vice President of Product and Test Engineering at OptimalPlus and Product Test Engineer at Intel Fab 18. He has been granted 14 patents in the United States, and has presented at various international conferences. David Hochman is a Managing Partner of Orchestra Medical Ventures, an investment firm that employs a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value and investor returns.  With more than 20 years of venture capital and investment banking experience, Mr. Hochman is also Chairman of Caliber Therapeutics, and a director Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), BackBeat Medical (where he is also President), Adgero Biopharmaceuticals, Inc. and FreeHold Surgical, Inc. In addition to being the Managing Director of Jacobs Investment Company, LLC, Mr. Jacobs serves on the boards of Next Generation Technologies and Fallbrook Technologies, Inc. and is also Chairman of Nutrina, Ltd., a biotechnology company focused on bioactive supplements for infant formulas. Mr. Korangy is a seasoned executive with broad expertise, having more than 20 years of experience in investing and operating roles across a wide range of industries. He currently serves as the Chief Financial Officer and Chief Strategy Officer of Beaver-Visitec International (“BVI”), a leading global developer, manufacturer and marketer of surgical devices for the ophthalmic marketplace. Prior to his appointment at BVI, Mr. Korangy was a senior executive at Novartis Group AG (NYSE: NVS), where he served as the Global Head of Corporate Finance. Prior to joining Novartis in 2010, Mr. Korangy served as a Managing Director at The Blackstone Group (NYSE: BX), where he spent approximately 15 years in the firm’s restructuring and private equity businesses. He currently serves on the Board of Directors of The Hain Celestial Group (NASDAQ: HAIN) and has previously served on several other public and private corporate boards. Dr. Samuel Nussbaum brings expertise across the spectrum of healthcare. Having served as the Chief Medical Officer of WellPoint/Anthem and, previously, Executive Vice President for BJC HealthCare, he has executive experience in population health, care management, data analytics, provider contracting, and medical and pharmacy policy and contracting. As a professor and clinical leader at Harvard Medical School and Massachusetts General Hospital he has led basic science research, drug discovery, clinical studies, teaching and patient care. Dr. Nussbaum received his undergraduate degree from New York University and his MD from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University and Massachusetts General Hospital and in endocrinology and metabolism at Harvard Medical School and Massachusetts General Hospital. Dr. Nussbaum is a Professor of Clinical Medicine at Washington University School of Medicine and serves as adjunct professor at the Olin School of Business, Washington University.